Biohaven (BHVN) investor relations material

Executive summary

• Achieved significant clinical milestones, including advancing BHV-1300 into Phase 3 for Graves' disease, presenting compelling data for Graves' disease and IgA nephropathy, and reporting durable seizure control for opakalim in epilepsy.

• Completed enrollment in pivotal epilepsy and obesity trials, with topline results expected in H2 2026.

• Expanded oncology pipeline with new data for BHV-1530 and advanced collaborations for ADC programs.

• No revenue generated from product sales; operations funded by equity and debt financings.

• Strategic reprioritization in Q4 2025 to optimize costs and value generation.

Financial highlights

• Net loss for Q2 2026 was $137.3M ($0.91/share), improved from $198.1M ($1.94/share) in Q2 2025.

• R&D expenses for Q2 2026 were $100.8M, down from $184.4M in Q2 2025, reflecting strategic reprioritization and lower milestone payments.

• G&A expenses for Q2 2026 were $24.1M, down from $27.3M year-over-year.

• Cash, cash equivalents, and marketable securities at June 30, 2026 totaled $270.5M.

• Non-GAAP adjusted net loss for Q2 2026 was $118.1M ($0.78/share), compared to $166.4M ($1.63/share) in Q2 2025.

Outlook and guidance

• Pivotal Phase 3 readouts for BHV-1300 in Graves' disease and opakalim in epilepsy expected in H2 2026.

• Pivotal study for BHV-1400 in IgA nephropathy to initiate in H2 2026.

• Cash, cash equivalents, and marketable securities expected to fund operations for at least one year from the report date.

• Continued advancement of pipeline candidates in neurology, immunology, and oncology.